This Week in Pharma: The Future of Moleculin’s Annamycin Post Celator Success and Dissecting Minerva’s Positive Phase 2b Results Summary:
This column discusses Moleculin’s Annamycin in the wake of Celator’s recent success with a similar drug and Minerva’s phase 2b data for schizophrenia drug MIN-101. Based on your votes for the more interesting topic, Slingshot Insights will sponsor the expert’s cost and you can join!
Option 1: Discussing Moleculin’s Annamycin after the company’s recent IPO, promising Phase 1, and Celator’s successful phase 3 trials for similar drug VYXEOS. What differentiates Annamycin, what does Celator’s success mean for Annamycin, and what are its chances of gaining approval?
Option 2: Examining Minerva’s MIN-101 positive …show more content…
Furthermore, On May 31, 2016, pharmaceutical companies Celator and Jazz announced entering into an agreement for Jazz to buy Celator at an 80%+ premium for $30.25/share (about $1.5 billion). The acquisition signals an interest in liposomal AML drugs by larger drug makers and their plausibility as a treatment option. Moleculin, whose main product Annamycin also aims to treat AML, IPO’d hot on the heels of Celator’s success (June 2, 2016), possibly trying to cash in on their momentum. MBRX raised approximately $9.5 million and this should allow them to proceed with Phase 2 trials for Annamycin. With MBRX still fresh on the publicly traded market, we are presented with a great opportunity to further investigate Annamycin and how CPXX’s success will impact the AML drug scene. Currently, drugs treating AML have low success rates and haven’t changed since the 1970’s, meaning any products which have demonstrated significant improvements in patient health like VYXEOS or Annamycin have the potential to be blockbuster drugs. Talking with a hematologic expert familiar could provide valuable insights into the landscape surround Annamycin, AML, and the chances of getting the drug
This column discusses Moleculin’s Annamycin in the wake of Celator’s recent success with a similar drug and Minerva’s phase 2b data for schizophrenia drug MIN-101. Based on your votes for the more interesting topic, Slingshot Insights will sponsor the expert’s cost and you can join!
Option 1: Discussing Moleculin’s Annamycin after the company’s recent IPO, promising Phase 1, and Celator’s successful phase 3 trials for similar drug VYXEOS. What differentiates Annamycin, what does Celator’s success mean for Annamycin, and what are its chances of gaining approval?
Option 2: Examining Minerva’s MIN-101 positive …show more content…
Furthermore, On May 31, 2016, pharmaceutical companies Celator and Jazz announced entering into an agreement for Jazz to buy Celator at an 80%+ premium for $30.25/share (about $1.5 billion). The acquisition signals an interest in liposomal AML drugs by larger drug makers and their plausibility as a treatment option. Moleculin, whose main product Annamycin also aims to treat AML, IPO’d hot on the heels of Celator’s success (June 2, 2016), possibly trying to cash in on their momentum. MBRX raised approximately $9.5 million and this should allow them to proceed with Phase 2 trials for Annamycin. With MBRX still fresh on the publicly traded market, we are presented with a great opportunity to further investigate Annamycin and how CPXX’s success will impact the AML drug scene. Currently, drugs treating AML have low success rates and haven’t changed since the 1970’s, meaning any products which have demonstrated significant improvements in patient health like VYXEOS or Annamycin have the potential to be blockbuster drugs. Talking with a hematologic expert familiar could provide valuable insights into the landscape surround Annamycin, AML, and the chances of getting the drug